Study wrapper · #48
Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.
Editor's note
A genuine preclinical efficacy study, not a review. In 24 male Wistar rats subjected to lower-limb ischemia-reperfusion, animals given BPC-157 showed significantly less histological damage in kidney, lung and liver tissue and higher antioxidant activity than controls. Because this is a randomized, sham-controlled rodent design with defined endpoints, it is a cleaner signal than the narrative reviews that dominate this literature, but it remains a small, single-model animal study. These are mechanistic findings; human data are needed before clinical conclusions can be drawn, and the effect on distant-organ protection has not been tested in people. It fits the broader pattern of consistent BPC-157 tissue-protection signals in rodents. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Plain-language abstract
This was an actual experiment, done in 24 male rats. The researchers briefly cut off and then restored blood flow to the animals' hind limbs, an injury that can also damage organs elsewhere in the body. Rats were split into four groups: a control group, a BPC-157-only group, an injury-only group, and an injury-plus-BPC-157 group. When the researchers examined the tissues afterward, the rats that received BPC-157 alongside the injury had noticeably less damage in their kidneys, lungs, and livers, and higher levels of protective antioxidant activity, compared with the other injured animals. This suggests BPC-157 reduced injury to distant organs in this rat model. It is an animal study only, so it cannot tell us whether the same would happen in people.